Last checked at 19 Sep 2017 07:00
Destiny Pharma plc
("Destiny" or "the Company")
Notice of Interim Results
Brighton, United Kingdom - 19 September, 2017 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel anti-microbial drugs, which address the global problem of anti-microbial resistance (AMR), will announce its maiden interim results for the six months ending 30 June 2017 on Wednesday 27 September 2017.
A meeting for analysts will be held at 11:00am BST on Wednesday 27 September at the offices of FTI Consulting, 200 Aldersgate Street, London EC1A 4HD.
Dial-in details for the live conference call will be made available on the Company's website.
For further information, please contact:
Destiny Pharma
Neil Clark, CEO
Simon Sacerdoti, CFO
pressoffice@destinypharma.com
+44 (0)1273 704 440
FTI Consulting
Simon Conway / Victoria Foster Mitchell / Hanna Skeppner
destinypharma@fticonsulting.com
+44 (0) 20 3727 1000
Cantor Fitzgerald Europe (Nominated Adviser and Broker)
Philip Davies / Will Goode, Corporate Finance
+44 (0)20 7894 8337
About Destiny Pharma
Destiny Pharma is an established, clinical stage, innovative biotechnology company focused on the development of novel medicines that represent a new approach to the treatment of infectious disease. These potential new medicines are being developed to address the need for new drugs for the prevention and treatment of life-threatening infections caused by antibiotic-resistant bacteria, often referred to as "superbugs". Tackling anti-microbial resistance has become a global imperative recognised by the WHO and the United Nations, as well as the G7 and the G20 countries. For further information, please visit https://www.destinypharma.com.